Voyager Therapeutics

Risk score

57

Headquarters

Flag of United States of AmericaUnited States of America

Voyager Therapeutics is dedicated to individuals suffering from severe neurological disorders. We aim to create transformative genetic treatments from initial research to market launch. Our primary focus is on individuals with severe neurological disorders for which safe and efficient treatment options are lacking, particularly in the realms of Parkinson's disease, a monogenic type of amyotrophic lateral sclerosis (ALS) referred to as SOD1, Huntington's disease, Friedreich's ataxia, Alzheimer's disease, and other neurodegenerative disorders associated with abnormal or excessive aggregation of tau and alpha-synuclein protein in the brain.